Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept plus FOLFIRI in metastatic colorectal cancer after oxaliplatin
2012-000048-89Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in metastatic colon cancer (mCRC), sponsored by Sanofi. Primary endpoint: Number of participants reporting adverse events. Started Aug 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2012-000048-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000048-89.